


PHARMACEUTICAL 2017

Avadel

AVADEL PHARMACEUTICALS PLC Rank 195 of 292





PHARMACEUTICAL 2017



AVADEL PHARMACEUTICALS PLC Rank 195 of 292

The relative strengths and weaknesses of AVADEL PHARMACEUTICALS PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVADEL PHARMACEUTICALS PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of AVADEL PHARMACEUTICALS PLC is the variable Other Liabilities, reducing the Economic Capital Ratio by 102% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 11% points above the market average of 2.9%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 181,186 |
| Cost of Goods Sold | 13,248 |
| Intangible Assets | 41,328 |
| Liabilities, Current | 62,421 |
| Liabilities, Non-Current | 5,822 |
| Other Assets | 19,648 |
| Other Compr. Net Income | -908 |
| Other Expenses | 102,242 |
| Other Liabilities | 135,170 |
| Other Net Income | 2,758 |
| Other Revenues | 150,246 |
| Property and Equipment | 3,320 |
| Research and Development | 34,611 |
| Selling, General and Administrative Expense | 44,179 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 245,482 |
| Liabilities | 203,413 |
| Expenses | 194,280 |
| Revenues | 150,246 |
| Stockholders Equity | 42,069 |
| Net Income | -41,276 |
| Comprehensive Net Income | -41,730 |
| Economic Capital Ratio | 14% |

